Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

E-067

Supelco

Ethosuximide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C7H11NO2
Numero CAS:
77-67-8
Peso molecolare:
141.17
Numero CE:
200-659-6
Codice UNSPSC:
41116107

Grado

certified reference material

Livello qualitativo

300

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

1.0 mg/mL in methanol

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
HAPOVYFOVVWLRS-UHFFFAOYSA-N

Informazioni sul gene

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

Descrizione generale

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

B-006

Butalbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

S-002

Secobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-008

Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-020

Amobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-024

Butabarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-041

Barbiturate Mix-5 solution, 250 μg/mL each component in methanol, ampule of 1.0 mL, certified reference material, Cerilliant®

H-013

Hexobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-010

Pentobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-075

Primidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Elenchi normativi

Forniamo informazioni su eventuali restrizioni prevalentemente per i prodotti chimici. Per altre tipologie di prodotto siamo in grado di fornire soltanto informazioni limitate. Nessuna segnalazione significa che nessuno dei componenti è citato in un elenco. È dovere dell’utilizzatore assicurarsi che il prodotto venga impiegato in maniera sicura e a norme di legge.

EU REACH Annex XVII (Restriction List)

CAS No.

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Emilio Russo et al.
Epilepsia, 52(7), 1341-1350 (2011-06-04)
Depression is most commonly associated with epilepsy. Recent reports have suggested a putative relationship between seizure development and onset of depressive behavior, whereas others proposed that two clinical entities might represent different neuropathologic aspects of the same neurologic disorder. The
Paolo Bonanni et al.
Developmental medicine and child neurology, 54(10), 961-964 (2012-03-15)
At 7 years of age, a female with mucopolysaccharidosis type II (MPS II) showed a sudden deterioration in neurological function, a sleep disorder, and progressive behavioural impairment. Electroencephalography was performed 1 year and 8 months after the onset of the
Gabi Dezsi et al.
Epilepsia, 54(4), 635-643 (2013-03-08)
Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. Chronic treatment with ESX has been reported to have disease-modifying antiepileptogenic activity in the WAG/Rij rat model of genetic generalized epilepsy (GGE) with absence seizures. Here
Dema M Ajwee et al.
Chemical biology & drug design, 79(1), 137-142 (2011-02-22)
The fact that ethosuximide (ETO), phenobarbital (PHO), and barbituric acid (BARB) share structural and pharmacophoric homologies with phenytoin and allantoin, both known to have significant wound-healing properties, prompted us to evaluate them as wound-healing agents. Accordingly, ETO-, PHO-, and BARB-containing
Gilles van Luijtelaar et al.
International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 85(1), 49-54 (2011-09-29)
Recently it was established that early long lasting treatment with the anti-absence drug ethosuximide (ETX) delays the occurrence of absences and reduces depressive-like symptoms in a genetic model for absence epilepsy, rats of the WAG/Rij strain. Here it is investigated
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.